Skip to main content


Volume 3 Supplement 2

21st European Workshop for Rheumatology Research

  • Meeting abstract
  • Open Access

Anti-skin anti-intercellular antibodies in juvenile idiopathic arthritis

  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Arthritis Research & Therapy20013 (Suppl 2) :P009

  • Received: 15 January 2001
  • Published:


  • Juvenile Idiopathic Arthritis
  • Psoriatic Arthritis
  • Pemphigus
  • Epidermolysis Bullosa
  • Immunofluorescence Antibody

The aim of this work was to study the presence of anti-skin anti-intercellular (ASA-IC) and anti-basement membrane (ASA-BM) antibodies of the IgG class in patients with juvenile idiopathic arthritis (JIA) without clinical features of chronic vesicular-bullous diseases including pemphigus, pemphigoid and epidermolysis bullosa acquisita (EBA).

No D-penicillamine was used for JIA management in this group due to a risk of drug-induced pemphigus. Indirect immunofluorescence antibody test (IIF) and dual substrates of monkey and guinea pig esophagus sections were used for the detection and quantification of ASA-IC as well as ASA-BM antibodies. Overall ASA-IC were detected in 50 out of 57 studied patients' sera samples (87,7 %, P = 0,0003) ranging from 1:20 to ≤ 1:320 dilutions. Respective of the classification criteria for idiopathic arthritis of childhood ASA-IC were observed in 6/6 patients with systemic disease (100%, P = 0,029), 24/29 patients with RF negative polyarthritis (82,7 %, P = 0,01), 16/18 RF positive polyarthritis (88,9 %, P = 0,0077) as well as in a small cohort of patients with oligoarthritis (2/2) and psoriatic arthritis (2/2). However we have observed a high incidence of anti-skin anti-intercellular antibodies in a cohort of patients with JIA we suggest that subclinical pemphigus occuring in this group might be exacerbated with different stimulus including pemphigus inducing drugs. No ASA-BM antibody positivity was observed in a cohort of 57 studied patients.



This research was supported by a European Commission (Acronym: EUROBANK, contract no: QOL-2000-14.1), web site and by grant of 2nd Medical Faculty, Charles University in Prague, VZ no. 111300003.

Authors’ Affiliations

2nd Paediatric Clinic, University Hospital Motol, Prague, Czech Republic


© BioMed Central Ltd 2001